Clinical trials: Allogeneic Stem-Cell Transplant
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
RATIONALE: Combining antithymocyte globulin with combination chemotherapy before donor peripheral stem cell transplantation may reduce the chance of developing graft-versus-host disease following transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00054340
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment.
- Conditions
- Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Trial name
- NCT02258490
- Testing
- G-CSF mobilized CD34+ selected cells for transplantation
- Where
- United States
- Sponsor
- Emory University
Allogeneic Hematopoietic Cell Transplantation
Precision Dosing of Alemtuzumab
The purpose of this study is to conduct a pilot trial of a Precision Dosing approach to alemtuzumab dosing for allogeneic hematopoietic cell transplantation of patients with non-malignant diseases.
- Trial name
- NCT03302754
- Testing
- Alemtuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation
Baricitinib for Post-HSCT Persistent Thrombocytopenia
This is a prospective, open-label phase 1b/2 clinical trial to explore the safety and efficacy profiles of baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia after allogeneic…
- Trial name
- BAPT (NCT07535645)
- Testing
- Baricitinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking University People's Hospital
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hematologic Malignancy
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in treating patients with blood cancer who are undergoing donor stem cell transplant.
- Trial name
- NCT02805075
- Testing
- Fructooligosaccharide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Allogeneic Stem Cell Transplant, Viral Infection
Donor-Derived Viral Specific T-cells (VSTs)
In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant.
- Conditions
- Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
- Trial name
- VSTs (NCT02048332)
- Testing
- Viral specific VST Infusion
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Primary Immunodeficiencies, Inborn Errors of Metabolism
Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases
The aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan compared to the conventional (myeloablative) dose of i.v.
- Conditions
- Primary Immunodeficiencies, Inborn Errors of Metabolism, Haemoglobinopathies, Bone Marrow Failure Syndromes
- Trial name
- NCT02349906
- Testing
- Treosulfan, Busilvex
- Where
- 21 sites in Czechia, Germany and 2 more
- Volunteers
- 106 people
- Sponsor
- medac GmbH
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
This phase II trial tests how well ibrutinib works in preventing chronic graft-versus-host disease (GVHD) in patients undergoing donor (allogeneic) hematopoietic cell transplantation (HCT).
- Trial name
- NCT06271616
- Testing
- Echocardiography Test, Ibrutinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
SIOD, Cystinosis
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT…
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis
- Trial name
- NCT05508009
- Testing
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alice Bertaina
Cancer
Chemotherapy Toxicity Reduction Via Urea Cycle Support
Patients undergoing bone marrow transplantation (BMT) and peripheral blood stem cell transplants (PBSCT) frequently develop organ dysfunctions, much of which may be initiated by damage to the liver and to cells lining blood…
- Trial name
- NCT00223730
- Testing
- Citrulline
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University
Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
The REACT Study: REhabilitation and ACTivity in Allogenic Transplant
A prospective, longitudinal cohort study will be conducted to evaluate the effects of treatment on the physical function of patients undergoing Allogeneic Hematopoeitic Stem Cell Transplant.
- Trial name
- REACT (NCT07581093)
- Volunteers
- 140 people
- Sponsor
- University of Dublin, Trinity College
Acute Myeloid Leukemia
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
This study is a single-center, single-arm, prospective phase II clinical trial evaluating the efficacy and safety of the VAH (Venetoclax and Azacitidine combined with Homoharringtonine) regimen, followed by allo-HSCT for…
- Trial name
- NCT06483906
- Testing
- Venetoclax, Azacitidine and Homoharringtonine
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation
Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation
This is a prospective, single-center, randomized controlled, investigator-initiated clinical study. The purpose of this study is to evaluate the efficacy and safety of Romiplostim N01 for Injection in promoting platelet…
- Trial name
- NCT07829952
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 87 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation
The MAC-HAPLO-MUD trial is a randomized prospective phase III trial comparing HLA 10/10 matched unrelated donor and haploidentical allogeneic hematopoietic stem cell transplantation after myeloablative conditioning regimen in…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myeloproliferative Syndromes, Myelodysplastic Syndromes
- Trial name
- MacHaploMud (NCT03655145)
- Testing
- Haplo donor stem cell transplantation, HLA 10/10 MUD stem cell transplantation
- Volunteers
- 344 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Leukemia
Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia
Allogeneic stem cell transplantation (Allo-HSCT) is the effective and even the only treatment for hematological malignancies. The "GIAC" protocol established by our center has successfully crossed the HLA barrier in…
- Trial name
- NCT03756675
- Testing
- haplotype PBSCT
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
This phase II trial studies how well itacitinib works in preventing graft versus host disease in patients with blood disorders undergoing donor stem cell transplantation.
- Conditions
- Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT04127721
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Fludarabine
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Diseases, Stem Cell Transplant Complications
ALLO-SCT in Elderly Patients With Hematological Disease
Retrospective, observational, multicentre, spontaneous, non-interventional study This study will evaluate all consecutive patients older than 60 years who received hematopoietic stem cell transplantation (HSCT) between 1st…
- Trial name
- NCT04386928
- Where
- 29 sites in Italy
- Volunteers
- 1,996 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Myelodysplastic Syndromes, Myeloid Leukemia
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT…
- Conditions
- Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
- Trial name
- NCT04628338
- Testing
- IFN-γ (interferon gamma-1b) injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sawa Ito, MD
Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL
T cell acute lymphoblastic leukemia (T-ALL)/Lymphoblastic lymphoma (LBL) is a hematological malignancy caused by malignant transformation and clonal expansion of T-lineage precursor cells.
- Trial name
- NCT05598593
- Testing
- cytarabine+thiotepa+ fludarabine + busulfan
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hematopoietic Stem Cell Transplantation (HSCT)
Comprehensive Palliative Care After Stem Cell Transplantation: a Feasability Study
People who receive an allogeneic stem cell transplant often face important physical and emotional challenges during their recovery.
- Trial name
- COMPAS (NCT07895693)
- Testing
- Early Integrated Palliative Care
- Where
- Switzerland
- Volunteers
- 42 people
- Sponsor
- Lisa Hentsch
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.